Abstract
Two recently published studies have investigated new modalities for the treatment of acute ischemic stroke. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group1 recently reported the results of a randomized, double-blind trial of intravenous recombinant tissue plasminogen activator (TPA) for acute ischemic stroke. There were two parts to the overall study; a total of 624 patients were randomized in both parts. To qualify for inclusion in either of the two parts, patients had to (1) have had an ischemic stroke with a clearly defined time of onset; (2) have a deficit that was measurable according to the National Institutes of Health Stroke Scale (NIHSS), a 42-point serial measure of neurological deficit; and (3) have a baseline computed tomographic brain scan that showed no evidence of intracranial hemorrhage. Patients had to have treatment with study drug initiated within 3 hours of symptom onset. Exclusion criteria included another stroke or head trauma within the past 3 months, major surgery within …
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
